{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265800","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.099921+00:00","generated_at":"2026-05-17T00:25:29.609064+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NewAmsterdam Pharma Q3 net loss widens to $72M; EMA accepts MAAs for obicetrapib","bullets":["Cash, equivalents and securities $756M as of Sep 30, 2025, down from $834.2M at Dec 31, 2024.","Net loss $72.0M in Q3 2025 vs $16.6M loss in Q3 2024; revenue fell to $0.3M from $29.1M.","European Medicines Agency accepted MAAs for obicetrapib monotherapy and FDC with ezetimibe.","R&D expenses $31.0M (down 13% YoY); SG&A $24.5M (up 33% YoY), driven by personnel and share-based compensation.","Ongoing Phase 3 trials: PREVAIL CVOT (>9,500 enrolled), REMBRANDT plaque imaging, and RUBENS (diabetes) expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265800","json":"https://secwatch.observer/filing/0001193125-25-265800.json","markdown":"https://secwatch.observer/filing/0001193125-25-265800.md","text":"https://secwatch.observer/filing/0001193125-25-265800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/0001193125-25-265800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:25:29.609064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}